Skip to content

Efficacy and safety evaluation of Jintiange capsule in the treatment of knee osteoarthritis: a single-center, double-blind, randomized, positive drug controlled trial

Efficacy and safety evaluation of Jintiange capsule in the treatment of knee osteoarthritis: a single-center, double-blind, randomized, positive drug controlled trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300078371
Enrollment
Unknown
Registered
2023-12-06
Start date
2024-01-01
Completion date
Unknown
Last updated
2023-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

knee osteoarthritis

Interventions

JinTiange capsule group:Jintiange capsule 3 capsules at a time, 3 times a day
Glucosamine sulfate group:Glucosamine sulfate group 250mg glucosamine sulfate, 2 capsules at a time, 3 times a day

Sponsors

Zibo Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: (1) Meet the description of knee osteoarthritis in the "Guidelines for the Diagnosis and Treatment of Osteoarthritis (2021 edition)", with obvious clinical symptoms such as knee pain, difficulty in squatting and mobility; (2) Kellgren Lawrence grade 1 or above of knee X-ray film; (3) Those who can take Jintiange capsule through TCM doctor's dialectic; Voluntary signing of informed consent.

Exclusion criteria

Exclusion criteria: ? Patients with cognitive impairment or other dysfunction who cannot complete the assessment; ? Patients with serious life-threatening primary diseases such as cardiovascular and cerebrovascular, liver, kidney and hematopoietic system and mental illness; ? Taking glucocorticoids and other drugs that may affect the efficacy; ? do not want to join the researcher; ? and affect the knee joint, such as: bone tuberculosis, bone tumor, knee joint acute trauma, infection, psoriasis, syphilitic neuropathy, etc.; ? knee joint skin damage; Voluntary signing of informed consent.

Design outcomes

Primary

MeasureTime frame
WOMAC score;SF-36 rating;

Secondary

MeasureTime frame
Time Up and Go test;6-minute walk test;adverse reaction;

Countries

China

Contacts

Public ContactMing Zhou

Zibo Central Hospital

18678187705@163.com+86 186 7818 7705

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026